Analyst firms · BofA Securities · EDIT
BofA Securities EDIT price target and rating history
Editas Medicine Inc. (EDIT) · Health Care
BofA Securities rates Editas Medicine Inc. (EDIT) Underperform with a $1 price target, as of its latest action on Nov 25, 2024. It has published 3 rating actions on EDIT since September 2022, including 1 upgrade and 1 downgrade. Across 3 firms with a EDIT price target in the last 12 months, the median target is $6.
- Current rating
- Underperform
- Price target
- $1
- Median target, all firms
- $6
- Actions on EDIT
- 3
BofA Securities price target on EDIT
Every BofA Securities rating on EDIT
- Nov 25, 2024
- Aug 8, 2024
- Sep 29, 2022
How other firms rate EDIT
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wells Fargo | Overweight | $6 | Oct 8, 2026 |
| Guggenheim | Buy | $5 | Sep 23, 2026 |
| Ladenburg Thalmann | Buy | $6 | Aug 18, 2026 |
Questions about BofA Securities and EDIT
- What is BofA Securities's price target for EDIT?
- BofA Securities's latest stated price target for Editas Medicine Inc. (EDIT) is $1, from its action on Nov 25, 2024.
- What is BofA Securities's rating on EDIT?
- BofA Securities rates EDIT Underperform, a bearish rating, as of Nov 25, 2024.
- When did BofA Securities last change its view on EDIT?
- On Nov 25, 2024, BofA Securities downgrades to Underperform from Buy, price target $13 to $1.
- How does BofA Securities's EDIT target compare with other analysts?
- Across 3 firms with a EDIT price target in the last 12 months, the median target is $6.
More EDIT rating histories
All BofA Securities ratingsEDIT news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.